Radiation Therapy in the Management of Adrenal Metastases

IF 2.6 3区 医学 Q3 ONCOLOGY Seminars in Radiation Oncology Pub Date : 2023-04-01 DOI:10.1016/j.semradonc.2022.11.001
Ciro Franzese MD , Sara Stefanini , Marta Scorsetti
{"title":"Radiation Therapy in the Management of Adrenal Metastases","authors":"Ciro Franzese MD ,&nbsp;Sara Stefanini ,&nbsp;Marta Scorsetti","doi":"10.1016/j.semradonc.2022.11.001","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Adrenal glands<span><span> represent a common site of metastases<span> from several primary tumors, including lung cancer, breast cancer and melanoma. Surgical resection is considered the </span></span>standard of care, but surgery is not always feasible given the challenges related to anatomical site and/or due to patient and/or disease characteristics. </span></span>Stereotactic body radiation therapy<span> (SBRT) represents a promising treatment for oligometastases, though the literature on its role for </span></span>adrenal metastases<span><span><span> is still heterogeneous. Herein are summarized the most relevant published studies on the efficacy and safety of SBRT for adrenal gland metastases. The preliminary data suggests that SBRT yields high local control rates and symptom relief with a mild pattern of toxicity. Advanced radiotherapy<span> techniques including IMRT and VMAT, a BED10 &gt; 72 Gy and the use of </span></span>4DCT for motion control should be considered for a high quality </span>ablative treatment of adrenal gland metastases.</span></p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"33 2","pages":"Pages 193-202"},"PeriodicalIF":2.6000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S105342962200073X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Adrenal glands represent a common site of metastases from several primary tumors, including lung cancer, breast cancer and melanoma. Surgical resection is considered the standard of care, but surgery is not always feasible given the challenges related to anatomical site and/or due to patient and/or disease characteristics. Stereotactic body radiation therapy (SBRT) represents a promising treatment for oligometastases, though the literature on its role for adrenal metastases is still heterogeneous. Herein are summarized the most relevant published studies on the efficacy and safety of SBRT for adrenal gland metastases. The preliminary data suggests that SBRT yields high local control rates and symptom relief with a mild pattern of toxicity. Advanced radiotherapy techniques including IMRT and VMAT, a BED10 > 72 Gy and the use of 4DCT for motion control should be considered for a high quality ablative treatment of adrenal gland metastases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
放射治疗在肾上腺转移瘤治疗中的应用
肾上腺是多种原发性肿瘤的常见转移部位,包括肺癌、癌症和黑色素瘤。手术切除被认为是护理的标准,但考虑到与解剖部位相关的挑战和/或由于患者和/或疾病特征,手术并不总是可行的。立体定向身体放射治疗(SBRT)是治疗少转移瘤的一种很有前途的方法,尽管关于其在肾上腺转移瘤中的作用的文献仍然不多见。本文总结了SBRT治疗肾上腺转移瘤的疗效和安全性的最相关的已发表研究。初步数据表明,SBRT可产生较高的局部控制率和症状缓解,并具有轻微的毒性模式。先进的放射治疗技术包括IMRT和VMAT、BED10>;对于肾上腺转移瘤的高质量消融治疗,应考虑使用72Gy和4DCT进行运动控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
48
审稿时长
>12 weeks
期刊介绍: Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
期刊最新文献
Radiation as an Immune Modulator: Where We Are With Modern Total Body Irradiation. Radiation for Multiple Myeloma in the Era of Novel Agents: Indications, Safety, and Dose Selection. Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma. Translating Between Radiation Dose and Late Toxicity for Lymphoma Survivors: Implications on Toxicity Counseling and Survivorship. Advanced Stage Hodgkin and Diffuse Large B-Cell Lymphomas: Is There Still a Role for Consolidation Radiotherapy in the PET Era?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1